BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...
Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...
Background: Schizophrenia is a chronic mental disorder that affects ~0.3-0.7% of the population worldwide and poses a significant economic and societal burden.
Objectives: To describe tr...
Objective: Limited data are available on patient characteristics and healthcare burden of schizophrenia in a healthcare system. This analysis examined the characteristics and healthcare b...
BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida.
Background: There is limited literature on treatment patterns, healthcare resourc...
Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...
Background
Schizophrenia (SCZ) likely leads to changes in and/or loss of employment, which can result in changes to insurance coverage or “churn”. Since patients with schizophrenia are ty...
Objectives: Investigate demographic, clinical, and economic factors associated with treatment initiation of paliperidone palmitate (PP) and aripiprazole LAI (ALAI) in Medicaid patients wi...
Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...